Compile Data Set for Download or QSAR
Report error Found 79 Enz. Inhib. hit(s) with all data for entry = 10208
TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520215(N-((1-Cyanopyrrolidin-3- yl)methyl)-1-(2,4-dichlor...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520255(US11130748, Example 68 | (R)-5-(3-Cyanophenyl)-N-(...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520256(US11130748, Example 69 | (S)-5-(3-Cyanophenyl)-N-(...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520242(US11130748, Example 55 | (R)-3-(3-Chlorophenyl)-N-...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520258(US11130748, Example 71 | (R)-1-(3-Cyanophenyl)-N-(...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520196(US11130748, Example 9 | (R)-3-(((5-Phenylthiazol-2...)
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520231(US11130748, Example 44 | 1-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520232(US11130748, Example 45 | 1-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520233(US11130748, Example 46 | N-((1-Cyanopyrrolidin-3-y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520234(US11130748, Example 47 | N-((1-Cyanopyrrolidin-3-y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520235(US11130748, Example 48 | 3-(1-((6-(5-Methylisoxazo...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520236(US11130748, Example 49 | 3-(1-((6-(1H-Pyrazol-4-yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520239(US11130748, Example 52 | 3-((Benzo[d]thiazol-2-yla...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520245(US11130748, Example 58 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520246(US11130748, Example 59 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520217(US11130748, Example 30 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520218(US11130748, Example 31 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520219(US11130748, Example 32 | (E)-N-((1-Cyanopyrrolidin...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520220(US11130748, Example 33 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520224(US11130748, Example 37 | 2-([1,1′-Biphenyl]-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520225(US11130748, Example 38 | N-((1-Cyanopyrrolidin-3-y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520228(US11130748, Example 41 | 1-(3-Chlorophenyl)-3-((1-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520229(US11130748, Example 42 | 1-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520230(US11130748, Example 43 | 1-(3-Benzylphenyl)-3-((1-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520264(US11130748, Example 77 | (R)-N-((1-Cyanopyrrolidin...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520265(US11130748, Example 78 | (R)-1-Benzyl-N-((1-cyanop...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520205(US11130748, Example 18 | Tert-butyl 3-(((3-(1,3-di...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520207(US11130748, Example 20 | N-((1-Cyanopyrrolidin-3-y...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520208(US11130748, Example 21 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520209(US11130748, Example 22 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520210(US11130748, Example 23 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520211(US11130748, Example 24 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520212(US11130748, Example 25 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520213(US11130748, Example 26 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520214(US11130748, Example 27 | N-((1-Cyanopyrrolidin-3- ...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520247(US11130748, Example 60 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520248(US11130748, Example 61 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520249(US11130748, Example 62 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520250(US11130748, Example 63 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520251(US11130748, Example 64 | (R)-N-((1-Cyano- pyrrolid...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520253(US11130748, Example 66 | (R)-3-(2-Chlorophenyl)-N-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520254(US11130748, Example 67 | (R)-3-(4-Chlorophenyl)-N-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520192(US11130748, Example 5 | 3-(((4-Phenylpyridin-2- yl...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520259(US11130748, Example 72 | (R)-1-(4-cyanophenyl)-N-(...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520260(US11130748, Example 73 | (R)-N-((1-Cyanopyrrolidin...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520261(US11130748, Example 74 | (R)-N-((1-Cyanopyrrolidin...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520197(US11130748, Example 10 | (S)-3-(((5-Phenylthiazol-...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520198(US11130748, Example 11 | 3-(((6-(1H-Pyrazol-4-yl)b...)
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520237(US11130748, Example 50 | 3-(1-(Isoquinolin-3-ylami...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 30(Human)
Mission Therapeutics

US Patent
LigandPNGBDBM520238(US11130748, Example 51 | 3-((1-(1-Cyanopyrrolidin-...)
Affinity DataIC50: 5.50E+3nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/8/2022
Entry Details
US Patent

Displayed 1 to 50 (of 79 total ) | Next | Last >>
Jump to: